MétaCan
Menu
Back to cohort
Record W2132793294 · doi:10.1093/eurheartj/eht307.p549

Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LY

2013· article· en· W2132793294 on OpenAlexaff
Robby Nieuwlaat, J. Healey, Michael D. Ezekowitz, Paul A. Reilly, Stephan Formella, Lars Wallentin, Salim Yusuf, Stuart J. Connolly

Bibliographic record

VenueEuropean Heart Journal · 2013
Typearticle
Languageen
FieldNursing
TopicVitamin K Research Studies
Canadian institutionsMcMaster UniversityHamilton Health Sciences
Fundersnot available
KeywordsMedicineInternal medicineRandomized controlled trialNauseaDabigatranAdverse effectWarfarinAtrial fibrillation

Abstract

fetched live from OpenAlex

Purpose: Data from the RE-LY trial showed that dabigatran etexilate (DE) was associated with more dyspepsia-like symptoms (DE 110 mg twice daily [bid] 11.8% total rate; 150 mg bid 11.3% total rate; dose independent) compared to well controlled warfarin (5.8% total rate). Almost 50% of the patients originally randomized to DE in the RE-LY trial were enrolled in the long-term follow-up study RELY-ABLE, where they continued to receive the blinded DE dose assigned in the RE-LY trial. Investigators completed specific case report forms (CRFs) during the RELY-ABLE trial to assess dyspepsia symptoms occurring at any time on DE treatment and whether specific measures provided symptom relief. Methods: A questionnaire in the CRFs collected descriptive information on the occurrence of dyspepsia and related events, the duration of episodes, therapies and responses to treatment. A total of 5851 patients were enrolled into the RELY-ABLE study (2914 on DE 110 mg bid and 2937 on 150 mg bid) and data were available from 5081 patients (86.8%). Patients were asked to describe the presence of new or worsening dyspepsia during their participation in the RE-LY and RELY-ABLE trials. If dyspepsia or a related event was reported, additional information regarding symptom alleviation and duration of symptoms was to be collected. Results: During the course of DE treatment 9.6% of patients (DE 110 mg and 150 mg bid) reported a period with dyspeptic symptoms; 2% reported prevalent dyspepsia; 6.8% reported previous and current dyspeptic symptoms. Occurrence of dyspepsia or abdominal discomfort was similar between the two DE dosages. The mean duration of dyspepsia symptoms was 44.7 days with DE 110 mg bid and 57.4 days with DE 150 mg bid. Overall, 1071 patients used 1123 treatments. The only treatments that appeared to reduce symptoms were concomitant food intake, proton pump inhibitors or H2-blocking agents (success rates 88%, 90% and 87%, respectively). Conclusion: Dyspepsia and related symptoms associated with the use of DE can be transient. If symptoms persist, some patients appear to benefit from measures that reduce stomach acidity. In RELY-ABLE, symptom improvement was reported with concomitant food intake, H2-blockers or proton pump inhibitors.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.004
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.035
GPT teacher head0.314
Teacher spread0.280 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart JournalSame topicVitamin K Research StudiesFrench-language works237,207